Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

Circulating microRNA (ct-miRNAs) are able to identify patients with differential response to HER2-targeted therapy. However, their dynamics are largely unknown. We assessed 752 miRNAs from 52 NeoALTTO patients with plasma pairs prior and two weeks after trastuzumab. Increased levels of ct-miR-148a-3...

Full description

Bibliographic Details
Main Authors: Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Marco Silvestri, José Baselga, Martine Piccart, Jens Huober, Miguel Izquierdo, Lorena de la Pena, Florentine S. Hilbers, Evandro de Azambuja, Michael Untch, Lajos Pusztai, Kathleen Pritchard, Paolo Nuciforo, Anne Vincent-Salomon, Fraser Symmans, Giovanni Apolone, Filippo G. de Braud, Marilena V. Iorio, Paolo Verderio, Maria Grazia Daidone
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:International Journal of Molecular Sciences
Subjects:
circulating micrornas
biomarkers
her2
breast cancer
trastuzumab
ct-mir-148a-3p
Online Access:https://www.mdpi.com/1422-0067/21/4/1386

Internet

https://www.mdpi.com/1422-0067/21/4/1386

Similar Items